Unknown Author
February 23, 2026
Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions
1 min
AI-made summary
- • Arrowhead Pharmaceuticals conducted concurrent public offerings of convertible notes, common stock, and pre-funded warrants, raising $930 million in gross proceeds. • Gibson Dunn represented Arrowhead Pharmaceuticals in these offerings and related capped call transactions for the convertible notes. • J.P
- Morgan Securities and Jefferies served as joint book-running managers for both the notes and equity offerings. • BofA Securities, Piper Sandler, and RBC Capital Markets also acted as joint bookrunners for both offerings. • The Gibson Dunn team included specialists in capital markets, derivatives, finance, and tax matters.
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.~~J.P. Morgan Securities and Jefferies acted as joint book-running managers for the notes offering and for the equity offering. BofA Securities, Piper Sandler, and RBC Capital Markets acted as joint bookrunners for both offerings.~~The Gibson Dunn capital markets team included partners Ryan Murr and Stewart McDowell and associates Lauren Navarro and Chad Kang. Partner Darius Mehraban and of counsel Adam Lapidus advised on derivatives matters. Partner Jin Hee Kim and associate Paul Rafla advised on finance matters. Partner Pamela Lawrence Endreny and associates Ryan Rott and Eytan de Gunzburg advised on tax matters.~~Download PDF~~
Article Author
Unknown Author
The Sponsor